PROM1 and melanoma: To further assess the effects of CD133 on the apoptotic response of melanoma cells exposed to single or combination treatment, Dox-inducible cells were incubated for 24 h with Dox to induce CD133 expression and then treated for 48 h with trametinib and capivasertib, alone or in combination, followed by Annexin flow cytometric apoptosis assays.